Joint health in severe hemophilia A with prophylaxis
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Severe hemophilia A diagnosis
- Currently on standard low-dose factor VIII prophylaxis 1–3 times per week for at least 6 months
- No history of factor VIII inhibitor (antibody level less than 0.6 Bethesda units)
- You and your parents must agree to participate and sign a consent form
- No other joint problems like osteoarthritis or metabolic bone disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study uses ultrasound to check if thickened joint lining (synovium) in people with severe hemophilia is a sign of active inflammation or just a harmless leftover. It may help doctors decide whether to treat or watch these joints.
This study looks at how two different hemophilia A treatments affect bone health over time. It tests if one medicine is better at keeping bones strong than the other.
This study looks at how hemophilia A affects joint health, balance, and quality of life in adults. Researchers will assess your joints and balance to understand the relationship between joint damage and everyday function.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.